Skip to main content
    I

    Inhibrx Biosciences, Inc. (INBX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $74.18
    -3.48 (-4.48%)

    Market Cap: $1.14B

    Last updated: Nov 17, 2026 at 4:15 PM ET

    Inhibrx Biosciences, Inc. (INBX) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Inhibrx Biosciences (INBX) has a market cap of $1.14B and an enterprise value of $1.22B. It kept -7082.90% of revenue as net income over the last 12 months. Revenue grew 42.86% over the last 12 months from the 12 months before.

    Total Valuation

    Enterprise value is 6.76% above the market cap, as debt exceeds cash.

    Market Cap$1.14B
    Enterprise Value$1.22B
    Latest price (Nov 17, 2026)$74.18

    Key Dates

    The next earnings report is expected on Mar 17, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 17, 2027 (expected)
    Last Earnings DateNov 13, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 0.33% in the quarter ended Sep 30, 2026 and grew 0.81% a year over 2 years.

    Shares Outstanding15.72M
    Shares Change (YoY)+1.56%
    Shares Change (QoQ)+0.33%
    Share Count Growth (2Y CAGR)+0.81%

    Price Statistics

    The stock is down 6.26% over 52 weeks and trades 20.74% below its 50-day average.

    Beta (1Y)2.17
    52-Week Change-6.26%
    1-Month Change-17.39%
    3-Month Change-26.90%
    6-Month Change-32.26%
    Total Return (1Y)-6.26%
    Return vs SPY (1Y)-15.95%
    Max Drawdown (1Y)-49.39%
    Max Drawdown (3Y)-49.39%
    Sharpe Ratio (1Y)-0.06
    Correlation with SPY (1Y)0.37
    50-Day Average$93.59
    200-Day Average$92.66
    52-Week Range$57.30 to $155.29
    RSI (14 Days)38.2
    Average Volume (20 Days)313.72K

    Price chart

    Financial Position

    Current assets cover 7.58x current liabilities.

    Current Ratio7.58x
    Quick Ratio7.58x
    Interest Coverage125.28x

    Returns and Efficiency

    Return on invested capital is -65.95% over the last 12 months.

    Return on Assets (ROA)-64.30%
    Return on Invested Capital (ROIC)-65.95%
    Return on Capital Employed (ROCE)-65.21%
    Asset Turnover0.01x
    Receivables Turnover12.05x

    Scores

    INBX has an Altman Z-Score of -0.87, in the distress zone below 1.81, and a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.

    Altman Z-Score-0.87
    Altman Z ZoneDistress
    Piotroski F-Score2 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue was $2.00M over the last 12 months.

    Revenue$2.00M
    Revenue Growth (YoY)+42.86%
    Gross Profit$1.44M
    Operating Income-$125.73M
    Pretax Income-$141.66M
    Net Income-$141.66M
    EBITDA-$118.90M
    EBIT-$125.85M
    Reported EPS (TTM)-$9.06

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Cash and Equivalents$199.47M
    Total Debt$276.70M
    Net Debt$77.23M
    Net Debt Per Share$4.91
    Working Capital$179.57M
    Shareholder Equity-$85.88M
    Total Assets$220.29M
    Total Liabilities$306.17M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    Operating Cash Flow-$132.67M
    FCF Per Share-$9.02
    Depreciation and Amortization$6.95M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -6286.70%.

    Gross Margin71.80%
    Operating Margin-6286.70%
    Pretax Margin-7082.75%
    Net Margin-7082.90%
    EBITDA Margin-5945.00%
    EBIT Margin-6292.50%

    Growth

    Revenue fell 15.98% a year over 3 years.

    Revenue Growth (3Y CAGR)-15.98%
    Book Value Per Share Growth (2Y CAGR)-19.93%
    Tangible Book Per Share Growth (2Y CAGR)-19.93%

    Revenue and profit by year

    Peer Position

    Against 6 similar companies, INBX has the highest P/S.

    P/S Ratio583.1x vs 4.1x median
    ROIC-65.95% vs -18.68% median
    Revenue Growth (Trailing 4 Quarters, YoY)+42.86% vs -43.59% median

    Competitors compared

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About INBX

    What is INBX's market cap?

    Inhibrx Biosciences has a market cap of $1.14B. Its enterprise value, which adds debt and subtracts cash, is $1.22B.

    How many shares of INBX are outstanding?

    Inhibrx Biosciences has 15.72M shares outstanding. The count is up 1.56% from a year earlier.

    Does INBX pay a dividend?

    No. Inhibrx Biosciences does not pay a dividend.

    How much debt does INBX have?

    Inhibrx Biosciences has $276.70M of total debt and $199.47M of cash and equivalents, a net debt position of $77.23M.